This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Zimmer-Biomet deal to enter second-phase review by European Commission

( October 2, 2014, 20:33 GMT | Official Statement) -- MLex Summary: Medical device company Zimmer Holdings said Thursday that the company expects to receive notice on Oct. 3 that the European Commission will open a second-phase review of its planned $13.35 billion acquisition of peer Biomet. The agency will have 90 working days, subject to possible extensions, to issue a decision on the matter. The deal is still expected to close in the first quarter of 2015.The full statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login